alitretinoin

Phase 3Completed

0 views this week 0 watching💤 Quiet

Interest: 34/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Hand Dermatoses

Conditions

Hand Dermatoses

Trial Timeline

Apr 1, 2006 → May 1, 2007

NCT ID

NCT00309621

About alitretinoin

alitretinoin is a phase 3 stage product being developed by Basilea Pharmaceutica for Hand Dermatoses. The current trial status is completed. This product is registered under clinical trial identifier NCT00309621. Target conditions include Hand Dermatoses.

What happened to similar drugs?

1 of 9 similar drugs in Hand Dermatoses were approved

Approved (1) Terminated (2) Active (6)

✅clobetasol propionateGSK plcApproved

🔄Lebrikizumab + PlaceboEli LillyPhase 3

🔄Pimecrolimus Cream 1%NovartisPhase 3

🔄tocilizumab + saline solutionRochePhase 3

🔄dupilumab + PlaceboSanofiPhase 3

❌Ruxolitinib cream + VehicleIncytePhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (5)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01407679	Phase 2	Terminated	Aug 1, 2011	Apr 1, 2014	Lupus Erythematosus, Cutaneous
NCT00519675	Phase 3	Completed	May 1, 2007	—	Eczema
NCT00309621	Phase 3	Completed	Apr 1, 2006	May 1, 2007	Hand Dermatoses
NCT00124436	Phase 3	Completed	Mar 1, 2005	Feb 1, 2007	Hand Dermatoses
NCT00124475	Phase 3	Completed	Dec 1, 2004	Sep 1, 2007	Hand Dermatoses

Competing Products

17 competing products in Hand Dermatoses

See all competitors

Product	Company	Stage	Hype Score
Lebrikizumab + Placebo	Eli Lilly	Phase 3	44
Methylprednisolone Tablet	Johnson & Johnson	Phase 2/3	34
ABT-981 + Placebo for ABT-981	AbbVie	Phase 2	35
Pimecrolimus Cream 1%	Novartis	Phase 3	40
tocilizumab + saline solution	Roche	Phase 3	40
denosumab + Placebo	Amgen	Phase 2	35
Dupilumab + Placebo	Sanofi	Phase 2	31
dupilumab + Placebo	Sanofi	Phase 3	40
clobetasol propionate	GSK plc	Approved	43
urea 40% cream + fluocinonide 0.05% cream + tazarotene 0.1% cream + bland emollient cream (Udderly smooth® Udder Cream)	Bayer	Phase 2	24
Ruxolitinib cream + Vehicle	Incyte	Phase 3	29
Ruxolitinib cream + Vehicle	Incyte	Phase 2	32
Ruxolitinib	Incyte	Phase 1/2	29
Ruxolitinib cream + Vehicle	Incyte	Phase 3	29
ARQ-252 cream 0.3% + ARQ-252 cream 0.1% + ARQ-252 Vehicle Cream	Arcutis Biotherapeutics	Phase 1/2	26
alitretinoin	Basilea Pharmaceutica	Phase 3	34
alitretinoin	Basilea Pharmaceutica	Phase 3	34